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Background: Commercially available hyaluronic acid (HA)-based fillers have distinct 
  physicochemical properties related to their specific manufacturing technology, including HA 
concentration, cross-linking percentage, and particle size. These factors may determine treatment 
effectiveness, safety, and longevity; however, this requires confirmation in the clinic.
Methods: To compare the efficacy, safety, and longevity of two distinct HA-based dermal 
fillers in the correction of severe nasolabial folds (NLFs), a 24 mg/mL smooth gel (Juvederm 
ULTRA PLUS™ [JUP]) and a 20 mg/mL particulate gel (Perlane® [PER]) were injected in a 
total of 80 normal, healthy subjects using a split face design and were followed for 12 months 
in this prospective, randomized, controlled, multicenter study.
Results: Both fillers achieved a clinically relevant NLF correction (one point or more improve-
ment, based on a validated NLF severity scale). However, JUP displayed greater longevity, with 
this correction maintained in a significantly larger percentage of NLFs after 6 months (physician’s 
evaluation) or 9 months (subject’s evaluation) and thereafter for the remainder of the study (70% 
vs 45%; P = 0.0002 and 62.5% vs 46.3%; P = 0.01 at month 12, based on physician and subject 
assessments, respectively). At month 12, 71.4% of the subjects nominated a preference for the 
NLF injected with JUP (P , 0.0001). Both treatments were well tolerated.
Conclusion: These results suggest that different physicochemical properties of HA-based 
fillers, associated with distinct manufacturing technologies, may influence treatment longevity 
in the correction of volume deficits. This may relate to a differential resistance to hyaluronidase 
and/or free radical degradation as previously documented in vitro.
Keywords: hyaluronic acid, dermal fillers, volume deficit, nasolabial folds, randomized, 
controlled
Introduction
Facial appearance is defined by properties of the skin, muscle, the bony anatomy, 
and the amount and distribution of subcutaneous adipose tissue. Structural changes 
in these tissues generally become noticeable by the age of 30 in the majority of the 
population.1,2 Loss of bone and soft tissue volume, redistribution of fat, and decreased 
dermal elasticity and thickness contribute to the formation of wrinkles and folds, 
which commonly characterize the aging process.3 In the case of the mid-face, an age-
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related decline in tensile strength of tissues supporting the 
nasolabial segment results in flattening and furrowing of the 
central area of the mid-cheek while displacement medially 
exaggerates the   volume and depth of the nasolabial fold 
(NLF).4–6   Correction of facial lines and wrinkles, as well as 
restoration and   alteration in facial shape, are key approaches 
to the rejuvenation and enhancement of facial appearance.4,7 
In addition to surgical treatments, injectable collagen, fat, and 
hyaluronic acid (HA)-based dermal fillers have been used 
over the past 20 years to achieve these goals.
HA is a naturally occurring glycosaminoglycan and a 
key component of the extracellular matrix in all adult animal 
tissue. Approximately 50% of the total HA concentration in 
the body is located in the dermis.8 Due to its high affinity for 
water, HA plays an integral role in maintenance and regula-
tion of moisture within tissues.9,10
Dermal fillers containing native HA polymer chains alone 
would have little therapeutic utility due to a rapid degrada-
tion through the activity of hyaluronidases and free radicals, 
which are present in high concentrations in the dermis. As a 
consequence, manufacturing processes associated with pro-
duction of HA-based dermal fillers are designed to change 
the physical and chemical properties of the HA, with the 
objective of improving resistance to this degradation in vivo, 
in addition to facilitating their safe and efficient administra-
tion via a syringe, at an acceptable extrusion force. This 
outcome is achieved for each of the commercially available 
HA-based dermal fillers through the application of different 
proprietary-based manufacturing technologies, leading to 
distinct properties of these fillers, including variances in HA 
concentration, the production of particulate or smooth gel 
masses, and associated differences in the degree of covalent 
binding of the HA polymers to cross-linking agents such as 
1,4-butanediol diglycidal ether (BDDE).10,11 Two such fillers 
are Juvederm ULTRA PLUS™ (JUP; Allergan Inc, Irvine, 
CA) and Perlane® (PER; Q-Med AB, Uppsala, Sweden). 
The final JUP product is a 24 mg/mL smooth, cohesive gel 
resulting from a proprietary cross-linking process involving 
BBDE, which forms a dense HA network. By contrast, the 
manufacture of PER is characterized by a lower relative 
degree of cross-linking by BDDE and, notably, a 20 mg/mL 
homogenous particulate gel mass resulting from the gel being 
pushed through a screen during a final production stage to 
create particles between 750 µm and 1000 µm.10–13
To investigate whether the aforementioned product char-
acteristics imparted a differential resistance to hyaluronidase 
activity, Sall and Ferard14 conducted in vitro evaluation of 
eleven commercially available gels, including JUP and PER. 
In this study, the PER gel was hydrolyzed at a significantly 
greater rate than for the JUP gel, reflecting a better stabil-
ity of the latter to this enzymatic degradation. The authors 
proposed that this greater relative resistance of JUP was due 
to its higher degree of HA polymer cross-linking, creating 
a more effective enzymatic barrier. Conversely, a larger HA 
surface area was available for hydrolysis in the particulate 
PER gel.
To test whether the differential degradation of these 
two dermal fillers in vitro would translate into a variance in 
their clinical performance, subjects with severe NLFs were 
enrolled into this multicenter, prospective, randomized, 
single-blind, within-subject (“split-face”) study. The primary 
objective of this study was to compare the efficacy, safety, 
and, specifically, the longevity of a single administration of 
JUP versus PER in the correction of NLFs over a period of 
12 months.
Methods
Subjects
Healthy male or female subjects aged 30 years or older with 
fully visible and symmetrical NLFs of a severe presenta-
tion, defined as a score of 3 on the five-point validated 
Physician’s Wrinkle Assessment/Nasolabial Fold Photonu-
meric Rating Scale (“NLF severity scale”),4 were eligible 
for the study. Exclusion criteria included any pre-existing 
condition that might affect efficacy and/or evaluation of 
response, including visible scars, active inflammation, 
infection, cancerous or precancerous lesions, and prior 
surgical cosmetic procedures in the treatment area. Subjects 
were excluded if any of the following criteria were met: a 
history of dermal filler or fat injections within 9 months of 
randomization, botulinum toxin treatment or mesotherapy 
within 6 months of randomization, and a history of per-
manent or semipermanent facial implants in the lower 
two-thirds of the face. A history of HA hypersensitivity, 
connective tissue disease, bleeding disorders, use of aspirin 
during the week preceding the study treatment, concomitant 
anticoagulant, or antiplatelet therapy were also exclusion 
criteria. During the study period, the use of antiwrinkle 
therapies in the area of the NLF or around the mouth was 
not permitted, with the exception of topical skincare prod-
ucts. Females of childbearing potential were required to 
have a negative urine pregnancy test and to use adequate 
contraception while participating in the study.
The study was approved by a central institutional review 
board and was conducted at four private dermatology clinics 
in accordance with the applicable Good Clinical Practice 
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  regulations and guidelines, including the International 
  Conference on Harmonization (ICH) guidelines. All sub-
jects were required to provide written informed consent 
prior to any study-related procedure. This study is listed 
on the Australian New Zealand Clinical Trial Registry 
(ACTRN12609000969268).
Treatment
In this within-subject comparator study, eligible subjects 
were randomly assigned to receive a single treatment with 
either JUP or PER into the right NLF, with the alternative 
treatment administered into the left NLF. No “touch-ups” 
were permitted during the study. As a commercial product 
was used in the trial, the physician investigators were not 
blinded to the product they were injecting. However, after 
the initial treatment session, the randomization code was 
kept in a location separate from the other study documents 
and was not freely available for review by the investigators. 
The subjects wore a blindfold during the injection procedure 
and were thus unaware of which product was injected into 
each NLF. This information was withheld from them for the 
entire duration of the 12-month study.
Before administration of the fillers, the treatment areas 
were prepared with antiseptic solution. The study products 
were injected into the mid to deep dermis (JUP) or deep der-
mis (PER), using a 27-gauge needle. The investigators were 
instructed to use as much product as deemed necessary (up 
to two syringes of each allocated product) to achieve optimal 
correction of the NLF. As neither study product contained lido-
caine in their formulation, the use of ice before and after the 
product administration was mandatory (topical or injectable 
anesthetic agents were not permitted, in order to minimize the 
potential for the distortion of the NLF region anatomy).
Outcome measures
The severity of each NLF was determined by the physician at 
baseline and at the scheduled clinic visits during the course of 
the study (days 3 and 7 and months 1, 3, 6, 9, and 12), based 
on the NLF severity scale. This scale ranges from none (“0”; 
“no wrinkle”) to extreme (“4”; “very deep wrinkle, redundant 
fold, overlapped skin”). A validated photonumeric guide 
was employed for this physician scale, comprising reference 
photographs that were labeled with descriptors for each of 
the five NLF severity grades.4 All physician investigators 
were trained to use this scale prior to study initiation.
At the same clinic visits, the study subjects were also 
asked to assess the severity of each NLF, using the NLF 
severity scale however without the photonumeric guide. 
This self-assessment was always completed prior to and 
independent of the physician assessment, with the scores 
documented on separate case report forms.
At the end of the study (month 12), while still blinded to 
the treatment allocation, subjects were asked to indicate their 
preferred treatment site (right or left NLF), if any, based on 
their perception of treatment outcome.
To evaluate the safety and tolerability of the two study 
treatments, on days 1 through 3 post-treatment, each subject 
kept a diary to record the degree of bruising, swelling, red-
ness, or pain at the injection site for each NLF. Subjects were 
also asked to evaluate the degree of pain they experienced at 
each NLF immediately following treatment (day 1), based 
on an eleven-point Likert scale, ranging from “no pain” to 
“worst pain imaginable”. The physician investigators also 
assessed each NLF on the initial two post-treatment follow-up 
clinic visits (days 3 and 7) for evidence of bruising, swelling, 
or redness. At these clinic visits, the subjects were asked to 
record the level of discomfort and tenderness on palpation 
using a 100-mm visual analog scale (VAS), ranging from 
“no discomfort (or tenderness)” to “worst discomfort (or 
tenderness) imaginable”.
Statistical analysis
All subjects receiving the study treatment were included in 
the efficacy and safety analyses. Missing efficacy data were 
replaced with those from the last available observation. In 
this within-subject study design, each patient was his/her own 
control, with the analysis based on the degree of correction at 
the left versus the right NLF for each subject, as determined 
by the independent rating of the physician and the subject 
over the 12-month post-treatment assessment period, using 
the validated NLF severity scale. Paired t-tests were used 
to evaluate the significance of continuous outcomes, and 
McNemar’s test was used to assess categorical outcomes. All 
statistical tests were two-sided, and P values , 0.05 were 
considered statistically significant.
A clinically meaningful treatment effect and the primary 
outcome variable for this study were defined as an improve-
ment (reduction) of one point or more on the NLF severity 
scale.15 An additional analysis was conducted based on an 
improvement of two points or more from baseline (ie, achiev-
ing a score of 0 (“no wrinkle”) or 1 (“shallow, just perceptible 
wrinkle”), again using the NLF severity scale.
For the subject’s treatment preference at month 12, a 
one-sample test of proportions was employed with a null 
hypothesis of an equal (50%) preference for missing data and 
the “no preference” response excluded from the analysis.
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Results
Subjects
A total of 80 subjects were enrolled, each receiving a single 
dose of the two study products into the right or left NLF, 
according to the randomization schedule. All subjects met 
the entry criterion of a score of 3 on the physician’s NLF 
severity scale for each NLF. The mean age of the subjects 
was 47.5 years (range 33–69 years), with the majority of 
the study population being female (95%) and Caucasian 
(95%). A total of 77 (96%) of the subjects completed the 
full 12-month study. Two subjects were lost to follow-up 
during the study (weeks 4 and 26, respectively), with a third 
subject withdrawing after 26 weeks due to a diagnosis of 
major depression, considered by the physician investigator 
to be unrelated to the treatment intervention.
Dosing
The physicians were permitted to administer up to two 
syringes each of the two study products into the allocated 
NLF, as stated previously. When analyzed, the mean volumes 
administered were similar: JUP 1.17 mL (range 0.6–1.6 mL) 
and PER 1.13 mL (range 0.6–2.0 mL; P = 0.22). No supple-
mentary administration (“touch-ups”) was allowed after the 
treatment day (day 1).
Efficacy
Primary outcome: one point or more improvement 
on the NLF severity scale
At the first post-administration assessment (day 3), the 
physicians judged that both NLFs had improved by one 
grade or better on the NLF severity scale in all 80 subjects, 
consistent with a clinically relevant improvement with both 
fillers. The subjects’ independent evaluation concurred, with 
99% (79/80) of NLFs treated with JUP and 95% (76/80) of 
NLFs treated with PER (P = 0.08) judged by the subjects to 
have achieved this outcome (Table 1).
When evaluated again at the three subsequent clinic 
visits (day 7; months 1 and 3), there was again no differ-
ence between the two treatments in the proportion of NLFs 
that had maintained this one point or better correction, as 
evaluated by both the physicians and the subjects (Table 1; 
Figures 1 and 2).
However, at month 6, differences in the clinical perfor-
mance began to consistently emerge, based on the ratings 
of both the physicians and subjects. At this clinic visit, 
this clinically relevant correction had been maintained 
in a significantly larger proportion of NLFs treated with 
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JUP, as documented by the physicians (90% vs 65%; 
P , 0.0001), with a clear trend also evident based on the 
subjects’ independent scoring (83.8% vs 72.5%; P = 0.06). 
By the month 9 visit, a statistically significant difference 
between the two dermal fillers was documented by both the 
physicians and the subjects, demonstrating a greater rela-
tive longevity for JUP in the maintenance of the clinically 
relevant correction (77.5% vs 57.5%; P = 0.0006 and 
75.0% vs 55.0%; P = 0.003, respectively). This differential 
effect in favor of JUP was confirmed at the final clinical 
visit for the study (month 12), again as documented by 
both the physicians and the subjects (70.0% vs 45.0%; 
P = 0.0002 and 62.5% vs 46.3%; P = 0.01, respectively) 
(Table 1; Figures 1 and 2).
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Figure 1 Proportion of nasolabial folds (NLFs) maintaining a clinically relevant improvement in the NLF severity score over the 12-month assessment period of the study 
(defined as: one point or greater improvement from the baseline score), as evaluated by the physician investigators.a
Note: aP values represent the difference between the two treatments from baseline, based on McNemar’s test.
Abbreviations: JUP, Juvederm ULTRA PLUS™; PER, Perlane®.
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Figure 2 Proportion of nasolabial folds (NLFs) maintaining a clinically relevant improvement in the NLF severity score over the 12-month assessment period of the study 
(defined as: one point or greater improvement from the baseline score), as evaluated by the subjects.a
Note: aP values represent the difference between the two treatments from baseline, based on McNemar’s test.
Abbreviations: JUP, Juvederm ULTRA PLUS™; PER, Perlane®.
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Secondary outcome: two points or greater 
improvement on NLF severity scale
When the analysis was conducted for the more rigorous 
endpoint of two grades or more improvement (ie, improv-
ing to 0 [“no wrinkle”] or 1 [“shallow, just perceptible 
wrinkle”] on the NLF severity scale at day 3), the physi-
cians and subjects also rated the treatments similarly at 
this clinic visit. However, by month 1, both the physicians 
and the subjects scored a significantly higher percentage 
of NLFs treated with JUP with a grade of 0 or 1, with the 
investigators independently documenting this outcome 
with JUP from as early as day 7. This differential effect 
for JUP was maintained for the remaining 11 months of 
the study (Table 1).
Safety and tolerability
Both treatments were well tolerated, with the majority of the 
treatment-related adverse events being transient, of mild-
to-moderate severity, and localized to the injection site. The 
individual parameters of pain, discomfort, or tenderness and 
other injection site reactions, as evaluated by the subject over 
the first 3 days postadministration, are summarized in this 
review and in Table 2. The physician’s evaluation of bruising, 
erythema, and swelling on days 3 and 7 post-treatment are 
summarized in Table 3.
Pain at injection site, postadministration (day 1)
As no anesthetic was used other than ice, the degree of pain 
following administration of the study treatments was rated 
by the subjects as moderate-to-severe. There was, however, 
no significant difference in the pain scores between the two 
study products as documented by the subjects on the eleven-
point VAS scale (Table 2).
Assessment of discomfort and tenderness  
(days 3 and 7)
The subjects reported a significantly higher degree of dis-
comfort on palpation on day 3 following the administration of 
PER, as assessed on a 100-mm VAS. This difference was not 
apparent by day 7. There was no difference reported between 
the two study treatments in the degree of tenderness on either 
day, again based on a 100-mm VAS (Table 2).
Other injection site reactions
Subject’s evaluation (days 1–3)
The subjects reported a significantly higher incidence of swell-
ing and pain on days 1 and 2 on the side treated with PER, as 
documented in their diaries. There was, however, no statistical 
difference between the two treatments in the incidence of 
bruising or redness over these three post-treatment days. By 
day 3, there was no difference between the two treatments 
for any of the injection site reactions (Table 2).
Physician’s evaluation (days 3 and 7)
The physicians reported a significantly higher incidence 
of bruising and swelling on day 7 following JUP treat-
ment. There was, however, no difference between the two 
treatments in the incidence of these events on day 3 or for 
the incidence of redness on either day according to the 
physicians (Table 3).
Subjects’ treatment preference
At month 12, while still blinded to the study treatment alloca-
tion, the 77 of 80 subjects completing this clinic visit were 
asked to document the preferred study product by nominat-
ing the NLF site that they believed had the best treatment 
outcome. Over 71% of the subjects identified the side treated 
with JUP, whereas 21% nominated PER, and the remaining 
Table 2 Incidence of injection site reactions (subject evaluation)a
Injection site reaction JUP PER
Postadministration pain  
(Day 1; eleven-point  
Likert scale) (mean ± SD)
6.1 ± 1.9 5.8 ± 2.1 (P = 0.23)
Subject diaries (days 1–3)
Presence of bruising (%)
  Day 1 70.1 71.4 (P = 0.80)
  Day 2 70.5 73.1 (P = 0.64)
  Day 3 63.3 59.5 (P = 0.56)
Presence of redness (%)
  Day 1 62.8 62.8 (P = 1.00)
  Day 2 43.6 50.0 (P = 0.13)
  Day 3 26.6 30.4 (P = 0.44)
Presence of swelling (%)
  Day 1 79.5 94.9 (P = 0.0005)
  Day 2 68.0 79.5 (P = 0.01)
  Day 3 51.9 55.7 (P = 0.44)
Presence of pain (%)
  Day 1 61.3 76.9 (P = 0.009)
  Day 2 32.1 48.7 (P = 0.009)
  Day 3 16.5 24.1 (P = 0.11)
Discomfort (100 mm VAS) (mean ± SD)
  Day 3 7.3 ± 12.8 11.1 ± 16.5 (P = 0.03)
  Day 7 2.7 ± 7.1 2.8 ± 9.6 (P = 0.83)
Tenderness (100 mm VAS) (mean ± SD)
  Day 3 9.9 ± 12.6 13.2 ± 20.5 (P = 0.15)
  Day 7 3.8 ± 8.8 3.1 ± 7.6 (P = 0.5)
Note: aP values represent the difference between treatments based on McNemar’s 
test.
Abbreviations:  JUP,  Juvederm  ULTRA  PLUS™;  PER,  Perlane®;  SD,  standard 
deviation; VAS, visual analog scale.
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8% of subjects reported no preference. When an analysis 
was conducted for subject preference for JUP versus PER 
only, this difference in favor of JUP was highly significant 
(z = 4.76, P , 0.0001; Figure 3).
Discussion
When assessed at the first post-treatment assessment (day 3), 
both dermal fillers achieved an equivalent outcome, with a 
clinically relevant improvement documented in 100% of 
NLFs, as rated by the physician investigators and in $95% 
of NLFs, as determined independently by the subjects, based 
on the validated NLF severity scale. Further, a large propor-
tion of the NLFs were rated by both the physicians (.72%) 
and the subjects ($60%) with a score of 0 or 1 on day 3, 
and this outcome was similar for both fillers (Table 1). This 
latter analysis was consistent with a complete or almost 
complete correction of the NLFs post-treatment,   suggesting 
that optimal NLF correction was achieved in a large percent-
age of subjects following a single administration of these 
two fillers.
This initial equivalence in the correction of the NLFs, in 
addition to the similar mean volume administered and the 
consistent safety and tolerability profiles of these two fillers, 
enabled a fair comparison of their durability over the entire 
12-month assessment period. Therefore, the greater relative 
longevity of the JUP in the maintenance of this clinically 
relevant correction, documented independently by both the 
physicians and the subjects after month 9 (based on one 
point or greater improvement), or after month 1 (for two 
points or greater improvement) on the NLF Severity Scale 
and preserved thereafter (Table 1; Figures 2 and 3), did not 
appear to be related to any specific differences in how the 
two fillers were initially administered.
A plausible explanation for this differential therapeutic 
effect observed in this study might be the distinct phys-
iochemical properties of these two products, defined by their 
proprietary-based manufacturing technologies, affording JUP 
greater resistance to degradation by hyaluronidases and free 
radicals. The JUP gel is produced using a two-stage cross-
linking process, resulting in a dense network of HA polymers 
that acts like a macromolecule. In comparison, PER consists 
of a relatively homogeneous gel mass of particles between 
750 µm and 1000 µm, produced by pushing the gel through a 
screen in the final production stage. Further, JUP has a higher 
0
No preference
PER
JUP
z = 4.76; P < 0.0001b
Subjects (%)
80 70 60 50 40 30 20 10
Figure 3 Treatment preference, as evaluated by the subjectsa at the end of the study (Month 12) while still blinded to the treatment allocation.
Notes: a77/80 subjects who completed the 12-month study; bP value based on a difference in subject preference for Juvederm ULTRA PLUS™ (JUP) versus Perlane® (PER) 
using a one-sample test of proportions with a null hypothesis of an equal (50%) preference for missing data and a “no preference” response excluded from the analysis.
Abbreviations: JUP, Juvederm ULTRA PLUS™; PER, Perlane®.
Table 3 Incidence of injection site reactions (physician evaluation)a
Injection site reaction JUP PER
Presence of bruising (%)
  Day 3 61.5 60.0 (P = 0.67)
  Day 7 28.8 11.3 (P = 0.001)
Presence of redness (%)
  Day 3 32.1 33.3 (P = 0.74)
  Day 7 21.3 18.8 (P = 0.41)
Presence of swelling (%)
  Day 3 36.6 29.5 (P = 0.32)
  Day 7 21.3 6.3 (P = 0.005)
Note: aP values represent the difference between treatments based on McNemar’s test.
Abbreviations: JUP, Juvederm ULTRA PLUS™; PER, Perlane®.
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relative degree of cross-linking to BDDE, which may create a 
more effective physical and chemical barrier to hyaluronase 
activity, thereby limiting access to its substrate, relative to 
the PER gel. Conversely, the distinct particles present in the 
PER gel may expose a greater relative surface area of its 
constituent HA to hydrolysis.10–13,16
The aforementioned hypothesis is consistent with the 
observations in a preceding in vitro study of the sensitivity 
of eleven HA gels to hyaluronase activity, in which the PER 
gel was hydrolyzed at a significantly faster rate than that for 
the JUP gel.14
In addition to the aforementioned, the higher relative 
HA concentration of JUP (24 mg/mL vs 20 mg/mL) might 
convey a greater lifting ability through the binding of more 
water molecules, in comparison with the PER gel, which may 
also contribute to the relative longevity of JUP as observed 
in the current study.4,10,11
A potential weakness in the design of this study is the 
physician investigator’s knowledge of the treatment alloca-
tion at the time of administration and thus the potential 
for bias during the outcome assessments over the ensuing 
12 months. However, the randomization code at each site 
was kept in a separate location to the other study documen-
tation and was therefore not freely accessible to the inves-
tigator after day 1. Further, as each investigator enrolled 
approximately 20 subjects, with all receiving both products, 
administered at similar mean volumes to the allocated NLFs, 
it would have been difficult for the investigator to recall the 
treatment randomization for any of the subjects over the 
12-month period of the study. Notably, there was a consis-
tency in the NLF scoring of the subjects and the physicians 
over the 12-month assessment (Table 1), with both groups 
independently recording their ratings on separate case report 
forms, which were not available to the other party. Finally, 
at the month 12 clinic visit, a majority (71.4%) of the sub-
jects nominated the NLF treated with JUP as their preferred 
treatment outcome while still blinded, further supporting the 
overall conclusions of this study.
Conclusion
In summary, the effectiveness of JUP, relative to PER, in 
the long-term maintenance of a clinically relevant correction 
of severe NLFs was clearly demonstrated in this 12-month 
within-subject study. As the mean volume administered into 
the allocated NLFs was virtually identical and the initial 
safety and efficacy of the two study products were very 
similar, a fair comparison of outcome for these two fillers is 
assumed. This greater apparent long-term durability of JUP 
may be related to its distinct physiochemical properties, 
affording it a greater relative resistance to enzymatic and/or 
free radical degradation in the dermis.
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